Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19303336 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNARECQLHTTL3MBTL1 | |
| SCHEMBL20362419 | 0.86 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNARECQLHTTKDM4E | |
| SCHEMBL19303424 | 0.84 | ATM (0.52) | SMN1; SMN2LMNAHTTL3MBTL1KDM4E | |
| SCHEMBL12705075 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNARECQLHTTL3MBTL1 | |
| SCHEMBL13025225 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNARECQLHTTL3MBTL1 | |
| SCHEMBL670003 | 0.81 | PLA2G7 (0.54) | SMN1; SMN2LMNARECQLHTTL3MBTL1 | |
| SCHEMBL670004 | 0.81 | PLA2G7 (0.54) | SMN1; SMN2LMNARECQLHTTL3MBTL1 | |
| SCHEMBL14077931 | 0.80 | PLA2G7 (0.53) | SMN1; SMN2LMNARECQLHTTL3MBTL1 | |
| SCHEMBL17831026 | 0.79 | SMN1; SMN2 (0.70) | SMN1; SMN2LMNARECQLHTTL3MBTL1 | |
| SCHEMBL18352131 | 0.79 | SMN1; SMN2 (0.70) | SMN1; SMN2LMNARECQLHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295092-A1 | 18F - TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND THEIR USE AS IMAGING AGENTS FOR PROSTATE CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2023-09-21 | — | — | US | disclosed |
| US-20180194729-A1 | 18F - TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND THEIR USE AS IMAGING AGENTS FOR PROSTATE CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2018-07-12 | — | — | US | disclosed |
| US-10016519-B2 | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | DEUTSCHES KREBSFORSCHUNGSZENTRIUM (DE) | 2018-07-10 | — | — | US | disclosed |
| US-20170246327-A1 | 18F-TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER | Ruprecht-Karls-Universität Heidelberg (DE) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194729-A1 | 18F - TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND THEIR USE AS IMAGING AGENTS FOR PROSTATE CANCER | KLK3, FOLH1, MPI | SMN1; SMN2 4749/4885LMNA 3679/4885RECQL 4350/4885 |
| US-10016519-B2 | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | KLK3, FOLH1, PSMA6 | SMN1; SMN2 4729/4885LMNA 3950/4885RECQL 4166/4885 |
| US-20230295092-A1 | 18F - TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND THEIR USE AS IMAGING AGENTS FOR PROSTATE CANCER | KLK3, FOLH1, MPI | SMN1; SMN2 4749/4885LMNA 3679/4885RECQL 4350/4885 |
| US-20170246327-A1 | 18F-TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER | KLK3, FOLH1, PSMA6 | SMN1; SMN2 4729/4885LMNA 3950/4885RECQL 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.